Nuvisan GmbH

Nuvisan GmbH is conducting research aimed at improving treatment options for pulmonary hypertension linked to left‑heart disease, focusing on safety and how new compounds behave in the body.

• Pulmonary hypertension due to left heart disease
• Evaluation of cardiovascular safety profiles
• Pharmacokinetic and pharmacodynamic assessments
• Early‑phase safety and tolerability studies

These efforts support the development of innovative cardiovascular therapies and help refine dosing strategies for patients with heart‑related conditions.

The clinical services team is exploring new approaches to manage vasomotor symptoms that arise from sex‑hormone fluctuations in both women and men, with an emphasis on efficacy and patient comfort.

• Vasomotor symptom relief strategies
• Hormone‑modulating agent evaluation
• Safety monitoring of hormone‑related treatments
• Quality‑of‑life impact assessments

By targeting hormone‑dependent disorders, Nuvisan aims to broaden therapeutic choices for individuals experiencing disruptive hot flashes and related signs.

Investigations at the site include studies on migraine, seeking to determine how emerging compounds can reduce attack frequency and improve patient outcomes while confirming safety.

• Migraine frequency reduction
• Neurological safety evaluation
• Pharmacodynamic profiling in healthy volunteers
• Early‑stage tolerability testing

These trials help pave the way for new migraine therapies that could offer relief to millions affected by this chronic neurological condition.

Researchers are addressing severe systemic responses such as sepsis‑associated disseminated intravascular coagulation, aiming to identify interventions that can mitigate life‑threatening complications.

• Sepsis and DIC therapeutic evaluation
• Biomarker monitoring for coagulopathy
• Safety assessments in acute care settings
• Impact on organ function and recovery

The work contributes to a deeper understanding of critical illness pathways and supports the development of treatments that could improve survival rates.

A core focus at Nuvisan involves comprehensive drug‑drug interaction studies, evaluating how multiple agents behave together in healthy participants to ensure future combination therapies are safe and effective.

• Multi‑drug interaction profiling
• First‑in‑human safety and tolerability
• Pharmacokinetic mapping of novel compounds
• Cross‑over design assessments for absorption and clearance

These investigations lay the groundwork for combination regimens across therapeutic areas, helping to predict and prevent adverse effects before larger patient trials begin.